A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
NCT02178956
Completed
The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Mayo Clinic - Arizona, Scottsdale, Arizona +262 locations
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Register for Updates
Trial of NanoPac Intratumoral Injection in Lung Cancer
NCT04314895
Completed
This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2023
Locations: University of Florida Health, Gainesville, Florida +3 locations
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
Register for Updates
A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
NCT02599363
Completed
This is a Phase I study to assess the safety and Maximum tolerated dose (MTD) of paclitaxel + ribociclib (LEE011) in patients with Rb+, advanced breast cancer. Dose escalation will be performed using standard 3 + 3 dosing strategy. The starting dose of ribociclib (LEE011) is 200 mg once daily; dose escalation proceeds in 200 mg increments up to a maximum of 600 mg. Dose-limiting toxicities (DLT) will be based upon first-cycle toxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2023
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Advanced Breast Cancer
Register for Updates
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
NCT04299880
Completed
This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated with napabucasin (monotherapy or combination) and who are deriving continued clinical benefit in the parent study at the time of closure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Winship Cancer Institute, Emory University, Atlanta, Georgia +6 locations
Conditions: Oncology
Register for Updates
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
NCT02584478
Active Not Recruiting
This trial is a Phase 1b/2a/3 trial designed to evaluate the safety and efficacy of adding oral AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to standard platinum-based chemotherapy concurrently in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: The Oncology Institute of Hope and Innovation, Long Beach, California +40 locations
Conditions: Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
Register for Updates
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
NCT02178436
Completed
This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping the... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
11/05/2023
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan +1 locations
Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
Register for Updates
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
NCT04016389
Recruiting
This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer. The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy dru... Read More
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
11/03/2023
Locations: MD Anderson Cancer Centre, Houston, Texas +3 locations
Conditions: Cervical Cancer
Register for Updates
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
NCT02013154
Completed
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Cedars Sinai Medical Care Foundation, Los Angeles, California +9 locations
Conditions: Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma
Register for Updates
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
NCT04247126
Completed
The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose expansion and will first administer SY-5609 in combination with gemcitabine and then SY-5609 in combination with gemcitabine and nab-paclitaxel in participants with pancreatic ductal adenocarcinoma (PDAC) .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +15 locations
Conditions: Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
Register for Updates
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
NCT04983407
Terminated
This is a Phase 1b/2 study of batiraxcept (AVB-S6-500) designed to evaluate the safety and efficacy of batiraxcept in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced, recurrent, or metastatic pancreatic adenocarcinoma as first line therapy. The phase 1b portion of the study is open label and patients will receive batiraxcept, nab-paclitaxel, and gemcitabine. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerabil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: UCLA Health, Santa Monica, California +16 locations
Conditions: Pancreatic Adenocarcinoma
Register for Updates
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT04729608
Terminated
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: University of South Alabama Mitchell Cancer Institute, Mobile, Alabama +149 locations
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates
The Chocolate Touch Study
NCT02924857
Active Not Recruiting
The Chocolate Touch study is a randomized, multi-center, prospective, adaptive study, designed to show sufficient safety and effectiveness of the Chocolate Touch™ for use in superficial femoral or popliteal arteries with the intention of obtaining regulatory approval to market this device in the United States
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Cardiac and Vascular Institute, Gainesville, Florida +19 locations
Conditions: Intermittent Claudication, Ischemia, Peripheral Artery Disease (PAD)
Register for Updates